Neurocrine

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.

About NBIX

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. 

CEO
Kyle W. Gano
CEOKyle W. Gano
Employees
2,000
Employees2,000
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1992
Founded1992
Employees
2,000
Employees2,000

NBIX Key Statistics

Market cap
15.84B
Market cap15.84B
Price-Earnings ratio
22.94
Price-Earnings ratio22.94
Dividend yield
Dividend yield
Average volume
1.09M
Average volume1.09M
High today
$156.75
High today$156.75
Low today
$154.61
Low today$154.61
Open price
$155.28
Open price$155.28
Volume
715.21K
Volume715.21K
52 Week high
$186.12
52 Week high$186.12
52 Week low
$122.14
52 Week low$122.14

Stock Snapshot

Neurocrine(NBIX) stock is priced at $155.92, giving the company a market capitalization of 15.84B. It carries a P/E multiple of 22.94.

As of 2026-08-28, Neurocrine(NBIX) stock has fluctuated between $154.61 and $156.75. The current price stands at $155.92, placing the stock +0.8% above today's low and -0.5% off the high.

Neurocrine(NBIX) shares are trading with a volume of 715.21K, against a daily average of 1.09M.

During the past year, Neurocrine(NBIX) stock moved between $122.14 at its lowest and $186.12 at its peak.

During the past year, Neurocrine(NBIX) stock moved between $122.14 at its lowest and $186.12 at its peak.

NBIX News

Simply Wall St 1d
How Investors May Respond To Neurocrine Biosciences Phase 4 INGREZZA Patient-Reported Benefit Data

Neurocrine Biosciences has reported Phase 4 KINECT-PRO results showing once-daily INGREZZA (valbenazine) led to substantial, sustained improvements in tardive d...

How Investors May Respond To Neurocrine Biosciences Phase 4 INGREZZA Patient-Reported Benefit Data
TipRanks 2d
Nxera to Book US$10m Milestone as FDA Clears Phase 2 Alzheimer’s Drug

Sosei Group ( (JP:4565) ) has provided an update. Nxera Pharma’s partner Neurocrine Biosciences has secured FDA IND acceptance for a Phase 2 trial of NBI-11175...

Simply Wall St 3d
Neurocrine Biosciences Stock Still Looks Like A Bargain Following Its 59% Run

Neurocrine Biosciences stock has delivered a 59.0% return over the past five years, yet its current valuation checks still lean on the cheap side rather than pr...

Neurocrine Biosciences Stock Still Looks Like A Bargain Following Its 59% Run

Analyst ratings

90%

of 30 ratings
Buy
90%
Hold
10%
Sell
0%

People also own

Based on the portfolios of people who own NBIX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.